An emerging COVID-19 variant, dubbed BA.3.2 and nicknamed “Cicada” by researchers, is under observation by public health officials due to its unusually high number of mutations. While current risks are low, the variant’s potential for rapid evolution raises concerns about future spread and immune evasion.
Current Status and Spread
As of March 2026, BA.3.2 has been detected in half the United States and 22 other countries. The Centers for Disease Control and Prevention (CDC) reports that this variant carries 70 to 75 mutations – at least double the number seen in the previously dominant JN.1 strains. Though currently accounting for only 0.19% of analyzed sequences, its presence in wastewater and clinical samples signals ongoing circulation.
Why the Mutations Matter
The sheer number of mutations in BA.3.2 is significant because it suggests a higher potential to bypass immunity from prior infections or vaccinations. Researchers note that the variant efficiently evades antibodies, likely due to changes in the spike protein. This means that while current vaccines are expected to still offer protection against severe illness, their effectiveness may be reduced.
International Trends
BA.3.2 has already made a noticeable impact in parts of Europe, accounting for 30% of samples in Denmark, Germany, and the Netherlands between November 2025 and January 2026. This indicates the variant’s ability to spread efficiently in certain populations.
The “Cicada” Analogy
Researchers have nicknamed the variant “Cicada” because it spent an extended period undetected before emerging more visibly in 2025. Like the insect, it appears to have been circulating in dormancy before becoming a more prominent strain.
What Experts Say
Andrew Pekosz, PhD, a virologist at Johns Hopkins Bloomberg School of Public Health, notes that while BA.3.2 is not currently an immediate threat, its continued evolution increases the risk of it becoming more contagious and virulent. Robert H. Hopkins, Jr., MD, medical director of the National Foundation for Infectious Diseases, agrees that while current vaccines may be less effective, more data is needed to determine the extent of the impact.
Common Symptoms
The symptoms of BA.3.2 infection are similar to other COVID strains, including:
- Sore throat
- Congestion or runny nose
- Cough
- Fever or chills
- Fatigue
- Muscle aches
- Headache
- Nausea/vomiting
- Diarrhea
- Shortness of breath
Severe sore throat is being reported as a common symptom.
Future Outlook
Whether BA.3.2 will drive a summer surge remains uncertain. However, experts emphasize the importance of continued genomic surveillance and vaccination efforts. As of March 17, 2026, COVID cases are declining in most areas of the U.S., but other respiratory viruses like flu and RSV overshadowed COVID this season.
The Bigger Picture
COVID-19 continues to be a public health concern, with over 3,500 deaths in the U.S. attributed to the virus in 2026 alone. Vigilance against all respiratory illnesses, including COVID, flu, and RSV, remains crucial. Improved vaccination rates and preventive measures are essential to protect communities from future outbreaks.
In conclusion, BA.3.2 is a concerning variant due to its high mutation rate, though it is not yet an immediate threat. Ongoing surveillance and continued vaccination remain critical to mitigate the potential risks of this evolving virus.
